Safety and efficacy of plerixafor dose escalation for the mobilization of CD34⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results

Affiliations

• ¹ Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York.
• ² Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York.
• ³ Bone Marrow and Hematopoietic Stem Cell Transplant Program, Weill Cornell Medicine/New York Presbyterian Hospital, New York.
• ⁴ Sickle Cell Program, Division of Hematology, Albert Einstein College of Medicine, Bronx.
• ⁵ Lindsley F. Kimball Research Institute, New York Blood Center, NY.
• ⁶ Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York.
• ⁷ Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, NY.
• ⁸ Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.